[Medical & Pharma] Launch of Medical MyData and Enactment of the Synthetic Biology Promotion Act

Korea Economic Daily

Aiming to enhance the transparency of drug and medical-device distribution and to block illegal kickbacks, the Ministry of Health and Welfare has disclosed, for the first time, the domestic pharmaceutical and medical-device industry's "reports on economic-benefit expenditures." A medical specialist attorney summarizes the risks of non-compliance with the law and emphasizes an overall review of compliance policies for pharmaceutical companies and CSOs.

Yakup Shinmun

Regarding the Digital Medical Products Act—the first of its kind to be enacted and put into force anywhere in the world—Attorney Lee Il-hyung examined the background and significance of this law, which has its own distinct framework different from the Medical Devices Act and the Pharmaceutical Affairs Act, including provisions on component performance evaluation and eased regulations and reviews.

Medipana

Choline alfoscerate preparations (hereinafter "choline preparations"), which have been prescribed as brain-function enhancers, are facing questions over their continued viability within the health-insurance reimbursement system. They now confront the Ministry of Health and Welfare and the National Health Insurance Service's demand for clinical reevaluation and a review of reimbursement appropriateness. Attorney Yoon So-young of the Medical and Pharmaceutical Group shares the implications of this affair, which has offered several significant lessons to the pharmaceutical industry as a whole.